Feldstein A - Search Results

1

The natural history of nonalcoholic fatty liver disease: a population-based cohort study.

Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. Adams LA, et al. Among authors: feldstein a. Gastroenterology. 2005 Jul;129(1):113-21. doi: 10.1053/j.gastro.2005.04.014. Gastroenterology. 2005. PMID: 16012941

2

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.

Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE. Alkhouri N, et al. PLoS One. 2018 Aug 30;13(8):e0202226. doi: 10.1371/journal.pone.0202226. eCollection 2018. PLoS One. 2018. PMID: 30161179 Free PMC article.

3

Steatohepatitis and apoptosis: therapeutic implications.

Feldstein A, Gores GJ. Feldstein A, et al. Am J Gastroenterol. 2004 Sep;99(9):1718-9. doi: 10.1111/j.1572-0241.2004.40573.x. Am J Gastroenterol. 2004. PMID: 15330908 No abstract available.

4

Severe hepatocellular injury with apoptosis induced by a hepatitis C polymerase inhibitor.

Feldstein A, Kleiner D, Kravetz D, Buck M. Feldstein A, et al. J Clin Gastroenterol. 2009 Apr;43(4):374-81. doi: 10.1097/MCG.0b013e318178d91f. J Clin Gastroenterol. 2009. PMID: 19098685 Free PMC article.

5

The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse.

Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. Canbay A, et al. Among authors: feldstein a. J Pharmacol Exp Ther. 2004 Mar;308(3):1191-6. doi: 10.1124/jpet.103.060129. Epub 2003 Nov 14. J Pharmacol Exp Ther. 2004. PMID: 14617689

6

Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls.

Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Patel NS, et al. Among authors: feldstein a. Gastroenterol Res Pract. 2013;2013:498296. doi: 10.1155/2013/498296. Epub 2013 Nov 17. Gastroenterol Res Pract. 2013. PMID: 24348536 Free PMC article.

7

Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction.

Adams LA, Feldstein A, Lindor KD, Angulo P. Adams LA, et al. Among authors: feldstein a. Hepatology. 2004 Apr;39(4):909-14. doi: 10.1002/hep.20140. Hepatology. 2004. PMID: 15057893

8

Nonalcoholic steatohepatitis: risk factors and diagnosis.

Adams LA, Feldstein AE. Adams LA, et al. Among authors: feldstein ae. Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):623-35. doi: 10.1586/egh.10.56. Expert Rev Gastroenterol Hepatol. 2010. PMID: 20932147 Review.

9

The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine CK, Feldstein AE, Alkhouri N. Mansoor S, et al. Dig Dis Sci. 2015 May;60(5):1440-7. doi: 10.1007/s10620-014-3494-7. Epub 2014 Dec 25. Dig Dis Sci. 2015. PMID: 25540086

10

Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.

Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Feldstein AE, et al. Am J Gastroenterol. 2013 Sep;108(9):1526-31. doi: 10.1038/ajg.2013.168. Epub 2013 Jun 11. Am J Gastroenterol. 2013. PMID: 23752877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results